Pharmacokinetic profile of a new controlled-release isosorbide-5-mononitrate 60 mg scored tablet (Monoket Multitab)

Eur J Pharm Biopharm. 2002 Jan;53(1):49-56. doi: 10.1016/s0939-6411(01)00210-7.

Abstract

The influences of food, tablet splitting, and fractional dosing on the pharmacokinetics of a new controlled-release double-scored tablet containing 60 mg isosorbide-5-mononitrate (Monoket Multitab) were investigated in healthy male volunteers. Food interaction was evaluated after single dose administration under fasted conditions and after a standard high-fat breakfast. The effect of tablet splitting was assessed at steady-state, after 5 days of once daily dosing with the tablet taken intact or trisected. The influence of fractional dosing was assessed after 1 and 6 days of daily regimen of 40 mg in the morning (2/3 of a tablet) and 20 mg in the evening (1/3 of a tablet). The pharmacokinetics of isosorbide-5-mononitrate after taking the tablet intact or in three fragments were very similar with a mere 10% increase of maximum plasma concentration (C(max)) for the latter, while the time to peak (T(max)) decreased from 5 to 4 h and areas under the concentration vs. time curves (AUCs) were virtually unchanged. Morning trough concentration reached 53 and 46 ng/ml, respectively. Administration of the intact tablet after a high-fat breakfast increased C(max) by 18% and AUC by 21%, and slightly delayed T(max) from 5 to 6h. During fractional dosing, morning and evening C(max) reached 364 and 315 ng/ml on the first day, and 373 and 300 ng/ml on the 6th day, respectively. The ratio of AUC(0-24 h) on the last day to AUC(infinity) on the first day, was 82.1% (confidence limits 71.7-94.1%) possibly resulting from peripheral volume expansion. The release characteristics of Monoket Multitab are thus moderately influenced by concomitant intake of food and to a very minor extent by tablet breaking. Fractional dosing allows to achieve lower peak and higher morning trough levels, while total exposure is comparable to that during once daily dosing (AUC(0-24 h, s.s.) of 5.55+/-1.78 and 5.71+/-1.08 microg h/ml).

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Analysis of Variance
  • Chemistry, Pharmaceutical
  • Cross-Over Studies
  • Delayed-Action Preparations / pharmacokinetics
  • Dietary Fats / metabolism
  • Drug Administration Schedule
  • Fasting / blood*
  • Food-Drug Interactions / physiology*
  • Humans
  • Isosorbide Dinitrate / administration & dosage
  • Isosorbide Dinitrate / analogs & derivatives
  • Isosorbide Dinitrate / blood
  • Isosorbide Dinitrate / pharmacokinetics*
  • Male
  • Middle Aged
  • Tablets
  • Vasodilator Agents / administration & dosage
  • Vasodilator Agents / blood
  • Vasodilator Agents / pharmacokinetics

Substances

  • Delayed-Action Preparations
  • Dietary Fats
  • Tablets
  • Vasodilator Agents
  • Isosorbide Dinitrate
  • isosorbide-5-mononitrate